BlackRock’s Boundless Bio BOLD Stock Holding History

BlackRock’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$77.7K	Buy	70,675 +3,627	+5%	+$4.24K	﹤0.01%	5019
2025 Q4	$80.5K	Buy	67,048 +1,674	+3%	+$2.09K	﹤0.01%	4953
2025 Q3	$80.4K	Buy	65,374 +1,116	+2%	+$1.29K	﹤0.01%	4886
2025 Q2	$64.9K	Sell	64,258 -563,939	-90%	-$749K	﹤0.01%	4936
2025 Q1	$949K	Sell	628,197 -20,974	-3%	-$43.5K	﹤0.01%	4203
2024 Q4	$1.88M	Buy	649,171 +240,485	+59%	+$701K	﹤0.01%	4051
2024 Q3	$1.42M	Sell	408,686 -108,408	-21%	-$393K	﹤0.01%	4094
2024 Q2	$2M	Buy	517,094 +367,094	+245%	+$3.51M	﹤0.01%	3965
2024 Q1	$2.14M	Buy	+150,000	New	+$2.14M	﹤0.01%	3982

Other funds holding BOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BlackRock's BOLD Position: Q1 2026 in Review

BlackRock increased its Boundless Bio (BOLD) stake by 5.4% in Q1 2026, buying an estimated $4.24K and bringing the position to 70,675 shares worth $77.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5019.

BlackRock first reported a position in BOLD in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.14M in Q1 2024. 36 funds tracked by Wall St. Rank hold BOLD as of Q1 2026.

BlackRock held 70,675 shares of Boundless Bio worth $77.7K as of Q1 2026.
BlackRock bought 3,627 Boundless Bio shares in Q1 2026, an estimated $4.24K.
Boundless Bio made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5019 holding.
BlackRock first reported a position in Boundless Bio in Q1 2024 and has held it in 9 quarters since.
BlackRock's Boundless Bio position peaked at $2.14M in Q1 2024.
36 funds tracked by Wall St. Rank held Boundless Bio as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.